{"id":"niacin-extended-release-lovastatin","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Flushing"},{"rate":"20-40","effect":"Pruritus"},{"rate":"5-10","effect":"Myalgia"},{"rate":"3-5","effect":"Elevated liver enzymes"},{"rate":"5-10","effect":"Hyperglycemia"},{"rate":"10-20","effect":"Gastrointestinal upset"}]},"_chembl":{"chemblId":"CHEMBL573","moleculeType":"Small molecule","molecularWeight":"123.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Niacin (vitamin B3) acts as a lipid-modifying agent that decreases hepatic triglyceride synthesis and VLDL production, while also increasing HDL cholesterol through multiple pathways. Lovastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. The combination provides complementary lipid-lowering effects for cardiovascular risk reduction.","oneSentence":"Niacin reduces triglycerides and LDL cholesterol while raising HDL cholesterol, and lovastatin inhibits HMG-CoA reductase to further lower LDL cholesterol.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:57:05.288Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperlipidemia and dyslipidemia for cardiovascular risk reduction"},{"name":"Primary and secondary prevention of coronary heart disease"}]},"trialDetails":[{"nctId":"NCT00271817","phase":"PHASE3","title":"To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":1220},{"nctId":"NCT00652431","phase":"PHASE1","title":"Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05","conditions":"Hypercholesterolemia, Hyperlipidemia","enrollment":18},{"nctId":"NCT00687076","phase":"PHASE4","title":"Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2004-04","conditions":"Peripheral Arterial Disease","enrollment":102},{"nctId":"NCT00479882","phase":"PHASE3","title":"MK-0524B Lipid Study (MK-0524B-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06-15","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":2414},{"nctId":"NCT01335997","phase":"PHASE3","title":"Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-01","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1139},{"nctId":"NCT00289900","phase":"PHASE3","title":"Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01-24","conditions":"Mixed Hyperlipidemia","enrollment":2340},{"nctId":"NCT01294683","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-02-04","conditions":"Primary Hypercholesterolemia, Dyslipidemia","enrollment":977},{"nctId":"NCT00880178","phase":"","title":"Plaque Inflammation and Dysfunctional HDL in AIM-HIGH","status":"COMPLETED","sponsor":"University of Washington","startDate":"2008-05","conditions":"Cardiovascular Diseases, Heart Diseases, Coronary Disease","enrollment":324},{"nctId":"NCT00359281","phase":"PHASE2","title":"Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2006-03","conditions":"Healthy","enrollment":125},{"nctId":"NCT01178320","phase":"","title":"Carotid Plaque Characteristics by MRI in AIM-HIGH (Carotid MRI Substudy)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2008-03","conditions":"Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis","enrollment":230},{"nctId":"NCT00120289","phase":"PHASE3","title":"Niacin Plus Statin to Prevent Vascular Events","status":"TERMINATED","sponsor":"Axio Research. LLC","startDate":"2005-09","conditions":"Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident","enrollment":3414},{"nctId":"NCT00804843","phase":"PHASE2","title":"Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04","conditions":"Carotid Atherosclerosis","enrollment":100},{"nctId":"NCT00479388","phase":"PHASE3","title":"Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1216},{"nctId":"NCT00461630","phase":"PHASE3","title":"Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-01","conditions":"Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus","enrollment":25673},{"nctId":"NCT00071266","phase":"PHASE3","title":"The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC","status":"COMPLETED","sponsor":"Kos Pharmaceuticals","startDate":"2003-10","conditions":"Intermittent Claudication, Peripheral Vascular Disease","enrollment":870},{"nctId":"NCT00062556","phase":"PHASE3","title":"Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication","status":"COMPLETED","sponsor":"Kos Pharmaceuticals","startDate":"2003-01","conditions":"Intermittent Claudication, Peripheral Vascular Disease","enrollment":366},{"nctId":"NCT00080275","phase":"PHASE3","title":"Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)","status":"COMPLETED","sponsor":"Kos Pharmaceuticals","startDate":"2004-03","conditions":"Hypercholesterolemia","enrollment":600},{"nctId":"NCT00082251","phase":"PHASE3","title":"Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST","status":"COMPLETED","sponsor":"Kos Pharmaceuticals","startDate":"","conditions":"Hypercholesterolemia","enrollment":""},{"nctId":"NCT00345657","phase":"PHASE4","title":"Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care","status":"COMPLETED","sponsor":"In His Image","startDate":"2003-07","conditions":"Hyperlipidemia, Mixed Hyperlipidemia, Dyslipidemia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Niacin Extended Release/Lovastatin","genericName":"Niacin Extended Release/Lovastatin","companyName":"In His Image","companyId":"in-his-image","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Niacin reduces triglycerides and LDL cholesterol while raising HDL cholesterol, and lovastatin inhibits HMG-CoA reductase to further lower LDL cholesterol. Used for Hyperlipidemia and dyslipidemia for cardiovascular risk reduction, Primary and secondary prevention of coronary heart disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}